IMPEDIMED LIMITED — Interim / Quarterly Report 2012

Aug 29, 2012

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text -----

ASX: IPD
----- End of picture text -----

30 August 2012

ASX RELEASE

ASX ANNOUNCEMENT – Annual Financial Report for 30 June 2012

Brisbane, Australia - ImpediMed Limited (ASX: IPD) (the Company) today released is Annual Financial Report for the year ended 30 June 2012, incorporating final audited results for the year.

ImpediMed Limited is pleased to provide the attached Appendix 4E, Preliminary Financial Report, relating to the Group’s performance for the financial year ending 30 June 2012.

Richard Carreon CEO

ENDS For further information contact:

Richard Carreon, ImpediMed CEO T: +1 (858) 412-0200 M: +1 (619) 309-6230

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to assist in the clinical assessment of unilateral lymphoedema of arm and leg in women and the leg in men by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 1 of 1

Appendix 4E Preliminary final report Period ending 30 June 2012

==> picture [410 x 540] intentionally omitted <==

----- Start of picture text -----

ImpediMed Limited - Appendix 4E
ABN 65 089 705 144
Preliminary final report
1 Current Financial Period Ended: 30 June 2012
Previous Corresponding Reporting Period: 30 June 2011
The information contained in this document should be read in conjunction with the ImpediMed Limited Financial Report for
the year ended 30 June 2012 and any public announcements made by ImpediMed Limited and its controlled entities during
the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.
2 Results for announcement to the market
Previous
Current reporting corresponding
period period
$000 $000
2.1 Revenue from ordinary activities $ 3,184 $ 4,172
Increase (decrease) in revenue ($000): $ (988)
Percentage increase (decrease): -24%
Note : With respect to the decrease in revenue from ordinary activities:
- medical business consumable and lease (including L-Dex) revenue increased slightly from the previous period to $0.76
million
- test & measurement division revenue decreased from $1.7 million to $1.1 million
- finance income decreased by less than $0.1 million
2.2 Profit/(loss) from ordinary activities after tax
attributable to members (12,342) (14,822)
Increase/(decrease) in profit from ordinary
activities after tax attributable to members ($000): $ 2,480
Percentage increase/(decrease): 17%
Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition to the decrease in
revenue above:
- foreign currency exchange loss included in administrative and governance expense decreased by $2.7 million
- salaries and benefits expense decreased by $0.7 million
- advertising and promotion costs increased by $0.3 million
- consultants and professional fees decreased by $0.1 million
- research and development expense increased by $1.4 million
2.3 Net profit/(loss) for the period attributable to members (12,342) (14,822)
Increase/(decrease) in net profit for the period
attributable to members ($000): $ 2,480
Percentage increase/(decrease): 17%
Note: Refer to 2.2 above and to the Directors' Report in the 2012 Financial Report.
3 Dividends
3.1 Dividends NIL
There were no dividends declared and paid during the reporting period on ordinary shares.
There were no dividends proposed and not yet recognised as a liability during the reporting period.
3.2 Dividend Record Date Not applicable
----- End of picture text -----

Appendix 4E Preliminary final report Period ending 30 June 2012

4		Financial Statements
	4.1	Statement of comprehensive income
		Refer to the Statement of Comprehensive Income in the 2012 Financial Report.
	4.2	Statement of financial position
		Refer to the Balance Sheet in the 2012 Financial Report.

4.3 Statement of cash flows Refer to the Cash Flow Statement in the 2012 Financial Report.

4.4 Statement of retained earnings Refer to the Statement of Changes in Equity in the 2012 Financial Report for movements in retained earnings.

5	Net tangible assets per security
					Previous
		Current reporting			corresponding
			period		period
5.1	Net tangible assets ($000)		15,458		18,605
	Issued share capital at reporting date ($000)		106,102		98,004
					Previous
		Current reporting			corresponding
			period		period
	Number of shares on issue at reporting date		181,314,055		156,497,061
	Net tangible assets per security	$	0.09	$	0.12
6	Earnings per security
					Previous
		Current reporting			corresponding
			period		period
	Weighted average number of ordinary shares (excluding reserved
6.1	shares) for basic earnings per share (EPS)		160,255,732		146,441,939
					Previous
		Current reporting			corresponding
			period		period
	Loss per share from continued operations
	Basic EPS	$	(0.08)	$	(0.10)
	Loss per share from profit attributable to ordinary shares
	Basic EPS	$	(0.08)	$	(0.10)
	Diluted earnings per share has been determined to be the same as basic	earnings per share as			the actual
	calculation is anti-dilutive for both periods presented.
	Refer t_o_Note 12_o_f the attached Financial Report for additional information pertaining to EPS for the current
	reporting period.
7	Acquisitions and divestments
	There were no entities over which control has been gained or lost during the		current reporting period.
8	Foreign entities
	Not applicable.
9	Associates and joint ventures
	Not applicable.
10	Commentary on results for the financial year
	Refer to the 2012 Financial Report.
11	Results of segments
	Refer to Note 6 operating segments in the 2012 Financial Report.
12	Audited Report
	The report is based on audited accounts which are not subject to dispute	or qualification.